Professor Todd Przybycien, Ph.D., head of RPI’s Department of Chemical and Biological Engineering, has been awarded a $3.1 million share of a Gates Foundation Global Grand Challenge grant to advance exceptionally low-cost monoclonal antibody (mAb) manufacturing. 

Monoclonal antibodies have proven effective at treating a wide range of conditions, including infectious diseases like COVID-19, autoimmune disorders, and certain types of cancer. But they are expensive to produce, and current market prices of $50 to $100 per gram put them effectively out-of-reach for millions of people around the world. 

The goal of the Gates Grand Challenge is to reduce the price of mAbs to just $10 per gram. Last month, the Gates Foundation announced $10.5 million in funding to a team led by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) in order to achieve that goal. Professor Przybycien’s group is part of that team and will focus on improving the process of purifying monoclonal antibodies after they have been produced by engineered cells.  

“Optimization and intensification of the downstream purification process offer the exciting possibility of breaking through to the $10/g overall target,” Przybycien said. “We are excited to advance the precipitation-based process we have developed with our collaborator at Penn State as part of the manufacturing solution to sustainably meet the global need for monoclonal antibodies.” 

Przybycien is an internationally recognized researcher in biomanufacturing and applied biophysics, focusing on developing processes to manufacture recombinant proteins, mRNA, and viral vectors. He has won numerous awards including the NSF CAREER Award and the Camille Dreyfus Teacher-Scholar Award. He is also a fellow of the American Chemical Society, AIChE, and AIMBE.   

“This grant is a testament to the years of work Todd Przybycien and his team have done to optimize and improve biopharmaceutical manufacturing processes,” said Shekhar Garde, Ph.D., the Thomas R. Farino, Jr. ’67 and Patricia E. Farino Dean of the School of Engineering. “It will pave the way for affordable access to lifesaving medications for millions of people who desperately need them.” 

“We are excited by the opportunity to demonstrate that there are existing solutions developed by industry and academic partners that can significantly reduce cost of goods and accelerate timelines,” said Kelvin Lee, NIIMBL Institute Director. “We are honored to receive this grant from the Gates Foundation, which will enable this exceptional team to deliver meaningful advances to antibody production efficiency.” 

This Gates Grand Challenge was established in honor of Dr. Steve Hadley, who championed the reduction of mAbs costs to make them affordable in low- and middle-income countries. 

The team’s first target will be a monoclonal antibody to treat malaria, an infectious disease which kills more than half a million people each year, primarily in Africa.